Fairmount Funds Management’s Apogee Therapeutics APGE Stock Holding History

Fairmount Funds Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.6M	Hold	298,647	–	–	2.62%	10
2026 Q1	$25.1M	Sell	298,647 -1,750,000	-85%	-$127M	1.82%	11
2025 Q4	$155M	Hold	2,048,647	–	–	11.77%	2
2025 Q3	$81.4M	Hold	2,048,647	–	–	7.32%	4
2025 Q2	$89M	Hold	2,048,647	–	–	11.53%	1
2025 Q1	$76.5M	Hold	2,048,647	–	–	11.87%	2
2024 Q4	$92.8M	Hold	2,048,647	–	–	9.23%	4
2024 Q3	$120M	Hold	2,048,647	–	–	9.76%	3
2024 Q2	$80.6M	Hold	2,048,647	–	–	9.11%	4
2024 Q1	$136M	Sell	2,048,647 -892,529	-30%	-$39M	14.84%	3
2023 Q4	$82.2M	Hold	2,941,176	–	–	8.68%	4
2023 Q3	$62.6M	Buy	+2,941,176	New	+$64.8M	7.54%	4

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fairmount Funds Management's APGE Position: Q2 2026 in Review

Fairmount Funds Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 298,647 shares worth $39.6M. The position accounts for 2.62% of the portfolio, ranked #10.

Fairmount Funds Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $155M in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Fairmount Funds Management held 298,647 shares of Apogee Therapeutics worth $39.6M as of Q2 2026.
Fairmount Funds Management left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 2.62% of Fairmount Funds Management's portfolio in Q2 2026, its #10 holding.
Fairmount Funds Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
Fairmount Funds Management's Apogee Therapeutics position peaked at $155M in Q4 2025.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.